Spots Global Cancer Trial Database for Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Official Title: A Phase I, Open-Label Study To Determine The Maximum Tolerated Dose (Mtd) Of The Combination Of Lenalidomide And Cetuximab, And To Evaluate The Efficacy Of This Combination In Subjects With Wild Type K-Ras Metastatic Colorectal Carcinoma

Study ID: NCT01126450

Conditions

Colon Cancer

Rectal Cancer

Interventions

lenalidomide

cetuximab

mutation analysis

polymerase chain reaction

polymorphism analysis

Study Description

Brief Summary: RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving lenalidomide together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with cetuximab in treating patients with metastatic colorectal cancer.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD). SECONDARY OBJECTIVES: I. To further explore the safety and efficacy profile. OUTLINE: This is a dose-escalation study of lenalidomide. Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days.